Amphastar Pharmaceuticals (NASDAQ:AMPH) (NASDAQ: AMPH) is a specialty pharmaceutical company engaged in the development, manufacturing and commercialization of inhalation and injectable products. Headquartered in Rancho Cucamonga, California, Amphastar focuses on creating both generic and proprietary therapies to address critical patient needs. Since its founding in 2004, the company has secured multiple U.S. Food and Drug Administration (FDA) approvals and built a diverse product portfolio that spans emergency care, hospital injectable solutions and respiratory therapies.
The company’s core product offerings include epinephrine injection products designed for acute allergic reactions, as well as a range of hospital-use injectables such as heparin, magnesium sulfate and insulin. In its inhalation segment, Amphastar markets generic asthma and COPD treatments, leveraging proprietary metered-dose inhaler technology. Beyond its own brands, the company provides contract manufacturing and fill-finish services, partnering with other pharmaceutical firms to produce inhalation devices and sterile injectables under cGMP standards.
Amphastar operates multiple state-of-the-art manufacturing facilities across North America, each equipped for sterile processing, device assembly and analytical testing. The company’s vertically integrated model helps ensure supply reliability for critical medications, while its logistics network supports distribution to hospitals, clinics, retail pharmacies and government agencies throughout the United States and select international markets. Amphastar continues to invest in capacity expansions, technology upgrades and process improvements to meet growing demand.
Leadership at Amphastar is anchored by founder and Chairman-CEO Alan Khurana, whose background in engineering and pharmaceutical sciences has shaped the company’s emphasis on innovation and quality control. Supported by a seasoned executive team, Amphastar pursues a balanced strategy of sustaining its core injectable and inhalation franchises while advancing a pipeline of new formulations. Through ongoing R&D partnerships and internal product development, the company aims to address emerging healthcare challenges and expand its footprint in critical therapeutic areas.
